Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer

Journal of the National Cancer Institute

Volumn 101, Issue 5, 2009, Pages 341-349

  Hackshaw, Allan ^a   Baum, Michael ^a   Fornander, Tommy ^b   Nordenskjold, Bo ^c   Nicolucci, Antonio ^d   Monson, Kathryn ^a   Forsyth, Sharon ^a   Reczko, Krystyna ^a   Johansson, Ulla ^b   Fohlin, Helena ^c   Valentini, Miriam ^d   Sainsbury, Richard ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Stockholm Breast Cancer Study Group   (Sweden)

^c South East Sweden Breast Cancer Group   (Sweden)

^d Gruppo Interdisciplinare Valutazione Interventi in Oncologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GONADORELIN; GOSERELIN; METHOTREXATE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; ATTRIBUTABLE RISK; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; EARLY CANCER; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; EUROPE; FEMALE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PREMENOPAUSE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 62349124975     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn498     Document Type: Article

References (18)

1. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 1996;17(1):47-67.
2. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351(9113):1393-1396.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
4. LHRH-agonists in Early Breast Cancer Overview Group. Use of luteinising hormone-releasing hormone (LHRH) agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369(9574):1711-1723.
5. Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in premenopausal patients with early breast cancer: results from the 'Zoladex ' in premenopausal patients (ZIPP) trial. Eur J Cancer. 2006;42(7):895-904.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-1467.
7. Collett D. Modelling Survival Data in Medical Research. Chapman and Hall, UK 1994.
8. Statistical Analysis Software (SAS), Version 9.1. Cary, NC: SAS Institute Inc.
9. Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005;23(25):5973-5982.
10. Barron TI, Connolly RM, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen. Cancer. 2007;109(5):832-839.
11. Bernhard J, Zahrieh D, Castiglione-Gertsch M, et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients - The International Breast Cancer Study Group Trial VIII. J Clin Oncol. 2007;25(3):263-270.
12. Aapro MS. Long-term complications of bone loss in breast cancer. Breast. 2004;13(suppl 1):s29-s37.
13. Fogelman I, Blake GM, Palmer M, et al. Bone mineral density in premenopausal women treated for node-negative early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int. 2003;14(12):1001-1006.
14. Sverrisdottir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE. Bone mineral density among premenopausal women with early breast cancer in a randomised trial of adjuvant endocrine therapy. J Clin Oncol. 2004;22(18):3694-3699.
15. Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25(7):820-828.
16. Brufsky A, Bundred N, Coleman R, et al.; for the Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008;13(5):503-514.
17. Gnant M, Mlineritsch B, Schippinger W, et al.; on behalf of the ABCSG. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12. J Clin Oncol. 2008;26 (suppl). Abstract LBA4.
18. Schmid P, Untch M, Kosse V, et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol. 2007;25(18):2509-2515.